
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1104610/publications.pdf Version: 2024-02-01



**STEVEN F Κ**ΛΗΝ

#	Article	IF	CITATIONS
1	Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature, 2006, 444, 840-846.	13.7	4,032
2	Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. New England Journal of Medicine, 2006, 355, 2427-2443.	13.9	2,714
3	Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 145-154.	13.9	2,294
4	Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-year results of the Look AHEAD trial. Diabetes Care, 2007, 30, 1374-1383.	4.3	1,369
5	Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet, The, 2014, 383, 1068-1083.	6.3	1,230
6	Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-11² in type 2 diabetes. Nature Immunology, 2010, 11, 897-904.	7.0	1,149
7	Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity. Journal of Biological Chemistry, 2004, 279, 12152-12162.	1.6	1,018
8	Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk. JAMA - Journal of the American Medical Association, 2019, 321, 69.	3.8	830
9	Intra-Abdominal Fat Is a Major Determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome. Diabetes, 2004, 53, 2087-2094.	0.3	813
10	The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4753-4761.	1.8	712
11	Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Contemporary Clinical Trials, 2003, 24, 610-628.	2.0	698
12	Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 4774-4779.	1.8	696
13	Glucose Levels and Risk of Dementia. New England Journal of Medicine, 2013, 369, 540-548.	13.9	696
14	Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1477-1490.	13.9	588
15	The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 4047-4058.	1.8	536
16	Rosiglitazone-Associated Fractures in Type 2 Diabetes. Diabetes Care, 2008, 31, 845-851.	4.3	498
17	Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 3629-3643.	1.8	495
18	Differences in A1C by Race and Ethnicity Among Patients With Impaired Glucose Tolerance in the Diabetes Prevention Program. Diabetes Care, 2007, 30, 2453-2457.	4.3	479

#	Article	IF	CITATIONS
19	Oral Disposition Index Predicts the Development of Future Diabetes Above and Beyond Fasting and 2-h Glucose Levels. Diabetes Care, 2009, 32, 335-341.	4.3	457
20	Prevention of Type 2 Diabetes With Troglitazone in the Diabetes Prevention Program. Diabetes, 2005, 54, 1150-1156.	0.3	442
21	Effect of Nateglinide on the Incidence of Diabetes and Cardiovascular Events. New England Journal of Medicine, 2010, 362, 1463-1476.	13.9	430
22	Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2019, 322, 1155.	3.8	423
23	Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program: Effects of Lifestyle Intervention and Metformin. Diabetes, 2005, 54, 2404-2414.	0.3	405
24	Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1654-1663.	1.8	384
25	Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet, The, 2012, 379, 2243-2251.	6.3	384
26	The Concurrent Accumulation of Intra-Abdominal and Subcutaneous Fat Explains the Association Between Insulin Resistance and Plasma Leptin Concentrations : Distinct Metabolic Effects of Two Fat Compartments. Diabetes, 2002, 51, 1005-1015.	0.3	362
27	Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults With Type 2 Diabetes. Diabetes Care, 2010, 33, 2156-2163.	4.3	313
28	Â-Cell Function Is a Major Contributor to Oral Glucose Tolerance in High-Risk Relatives of Four Ethnic Groups in the U.S Diabetes, 2002, 51, 2170-2178.	0.3	286
29	Gestational Diabetes Mellitus Increases the Risk of Cardiovascular Disease in Women With a Family History of Type 2 Diabetes. Diabetes Care, 2006, 29, 2078-2083.	4.3	284
30	Is central obesity associated with cirrhosis-related death or hospitalization? A population-based, cohort study. Clinical Gastroenterology and Hepatology, 2005, 3, 67-74.	2.4	283
31	Ghrelin Suppresses Glucose-Stimulated Insulin Secretion and Deteriorates Glucose Tolerance in Healthy Humans. Diabetes, 2010, 59, 2145-2151.	0.3	281
32	β-Cell Loss and β-Cell Apoptosis in Human Type 2 Diabetes Are Related to Islet Amyloid Deposition. American Journal of Pathology, 2011, 178, 2632-2640.	1.9	271
33	Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet, The, 2021, 398, 1811-1824.	6.3	257
34	The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism: Clinical and Experimental, 1991, 40, 545-551.	1.5	252
35	CENTRAL INSULIN ADMINISTRATION REDUCES NEUROPEPTIDE Y mRNA EXPRESSION IN THE ARCUATE NUCLEUS OF FOOD-DEPRIVED LEAN (Fa/Fa) BUT NOT OBESE (fa/fa) ZUCKER RATS. Endocrinology, 1991, 128, 2645-2647.	1.4	248
36	The Atherogenic Lipoprotein Profile Associated With Obesity and Insulin Resistance Is Largely Attributable to Intra-Abdominal Fat. Diabetes, 2003, 52, 172-179.	0.3	243

#	Article	IF	CITATIONS
37	Visceral Adiposity Is an Independent Predictor of Incident Hypertension in Japanese Americans. Annals of Internal Medicine, 2004, 140, 992.	2.0	234
38	Rationale and Design of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care, 2013, 36, 2254-2261.	4.3	217
39	The prevention of type 2 diabetes. Nature Clinical Practice Endocrinology and Metabolism, 2008, 4, 382-393.	2.9	216
40	A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care, 2002, 25, 1737-1743.	4.3	215
41	Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?. Diabetes Care, 2011, 34, 1424-1430.	4.3	214
42	Effects of Rosiglitazone, Glyburide, and Metformin on β-Cell Function and Insulin Sensitivity in ADOPT. Diabetes, 2011, 60, 1552-1560.	0.3	208
43	Disproportionately Elevated Proinsulin in Pima Indians with Noninsulin-Dependent Diabetes Mellitus*. Journal of Clinical Endocrinology and Metabolism, 1990, 70, 1247-1253.	1.8	198
44	Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA <sup>®</sup> ). Diabetes and Vascular Disease Research, 2015, 12, 164-174.	0.9	197
45	Elevated Depression Symptoms, Antidepressant Medicine Use, and Risk of Developing Diabetes During the Diabetes Prevention Program. Diabetes Care, 2008, 31, 420-426.	4.3	193
46	Visceral Adiposity and the Risk of Impaired Glucose Tolerance: A prospective study among Japanese Americans. Diabetes Care, 2003, 26, 650-655.	4.3	191
47	Obesity, Body Fat Distribution, Insulin Sensitivity and Islet β-Cell Function as Explanations for Metabolic Diversity. Journal of Nutrition, 2001, 131, 354S-360S.	1.3	181
48	Minimum Waist and Visceral Fat Values for Identifying Japanese Americans at Risk for the Metabolic Syndrome. Diabetes Care, 2007, 30, 120-127.	4.3	178
49	Impact of Intensive Lifestyle Intervention on Depression and Health-Related Quality of Life in Type 2 Diabetes: The Look AHEAD Trial. Diabetes Care, 2014, 37, 1544-1553.	4.3	178
50	Visceral Adiposity, Not Abdominal Subcutaneous Fat Area, Is Associated With an Increase in Future Insulin Resistance in Japanese Americans. Diabetes, 2008, 57, 1269-1275.	0.3	177
51	Disproportionately Elevated Proinsulin Levels Reflect the Degree of Impaired B Cell Secretory Capacity in Patients with Noninsulin-Dependent Diabetes Mellitus <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 604-608.	1.8	175
52	The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus11Supported in part by National Institutes of Health grants DK-02654, DK-17047, DK-50703, and the Medical Research Service of the Department of Veterans Affairs American Journal of Medicine, 2000, 108, 2-8.	0.6	175
53	Updated Genetic Score Based on 34 Confirmed Type 2 Diabetes Loci Is Associated With Diabetes Incidence and Regression to Normoglycemia in the Diabetes Prevention Program. Diabetes, 2011, 60, 1340-1348.	0.3	172
54	Obesity Is a Major Determinant of the Association of C-Reactive Protein Levels and the Metabolic Syndrome in Type 2 Diabetes. Diabetes, 2006, 55, 2357-2364.	0.3	169

#	Article	IF	CITATIONS
55	Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes, 2015, 64, 673-686.	0.3	165
56	Effect of Rosiglitazone, Metformin, and Glyburide on Bone Biomarkers in Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 134-142.	1.8	164
57	Regression From Pre-Diabetes to Normal Glucose Regulation in the Diabetes Prevention Program. Diabetes Care, 2009, 32, 1583-1588.	4.3	155
58	Phenotypic Characteristics of GAD Antibody-Positive Recently Diagnosed Patients With Type 2 Diabetes in North America and Europe. Diabetes, 2004, 53, 3193-3200.	0.3	154
59	Progressive Loss of Â-Cell Function Leads to Worsening Glucose Tolerance in First-Degree Relatives of Subjects With Type 2 Diabetes. Diabetes Care, 2007, 30, 677-682.	4.3	152
60	Adiponectin, Change in Adiponectin, and Progression to Diabetes in the Diabetes Prevention Program. Diabetes, 2008, 57, 980-986.	0.3	151
61	Impact of an Intensive Lifestyle Intervention on Use and Cost of Medical Services Among Overweight and Obese Adults With Type 2 Diabetes: The Action for Health in Diabetes. Diabetes Care, 2014, 37, 2548-2556.	4.3	144
62	Adherence to Preventive Medications: Predictors and outcomes in the Diabetes Prevention Program. Diabetes Care, 2006, 29, 1997-2002.	4.3	136
63	Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: Rationale for the active-comparator CAROLINA trial. Diabetes and Vascular Disease Research, 2013, 10, 289-301.	0.9	132
64	Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia, 2017, 60, 1601-1611.	2.9	129
65	Metabolic Contrasts Between Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes: I. Observations Using the Hyperglycemic Clamp. Diabetes Care, 2018, 41, 1696-1706.	4.3	127
66	The Dipeptidyl Peptidase-4 Inhibitor Vildagliptin Improves β-Cell Function and Insulin Sensitivity in Subjects With Impaired Fasting Glucose. Diabetes Care, 2008, 31, 108-113.	4.3	126
67	Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation, 2019, 139, 351-361.	1.6	126
68	Proinsulin as a Marker for the Development of NIDDM in Japanese-American Men. Diabetes, 1995, 44, 173-179.	0.3	125
69	Heritability of Pancreatic β-Cell Function among Nondiabetic Members of Caucasian Familial Type 2 Diabetic Kindreds1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 1398-1403.	1.8	125
70	Effect of Weight Loss with Reduction of Intra-Abdominal Fat on Lipid Metabolism in Older Men*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 977-982.	1.8	125
71	Effects of the Type 2 Diabetes-AssociatedPPARGP12A Polymorphism on Progression to Diabetes and Response to Troglitazone. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1502-1509.	1.8	122
72	Diet Intervention and Cerebrospinal Fluid Biomarkers in Amnestic Mild Cognitive Impairment. Archives of Neurology, 2011, 68, 743-52.	4.9	122

#	Article	IF	CITATIONS
73	Visceral Adiposity and the Prevalence of Hypertension in Japanese Americans. Circulation, 2003, 108, 1718-1723.	1.6	121
74	Differential effect of inbred mouse strain (C57BL/6, DBA/2, 129T2) on insulin secretory function in response to a high fat diet. Journal of Endocrinology, 2005, 187, 45-53.	1.2	119
75	Type 2 Diabetes–Associated Missense Polymorphisms KCNJ11 E23K and ABCC8 A1369S Influence Progression to Diabetes and Response to Interventions in the Diabetes Prevention Program. Diabetes, 2007, 56, 531-536.	0.3	115
76	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care Editors' Expert Forum. Diabetes Care, 2016, 39, 1186-1201.	4.3	113
77	The Contribution of Insulin-Dependent and Insulin-Independent Glucose Uptake to Intravenous Glucose Tolerance in Healthy Human Subjects. Diabetes, 1994, 43, 587-592.	0.3	112
78	Impact of Insulin and Metformin Versus Metformin Alone on β-Cell Function in Youth With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2018, 41, 1717-1725.	4.3	112
79	Insulin binding to brain capillaries is reduced in genetically obese, hyperinsulinemic Zucker rats. Peptides, 1990, 11, 467-472.	1.2	111
80	Optimum BMI Cut Points to Screen Asian Americans for Type 2 Diabetes. Diabetes Care, 2015, 38, 814-820.	4.3	108
81	Increased Dietary Fat Promotes Islet Amyloid Formation and Â-Cell Secretory Dysfunction in a Transgenic Mouse Model of Islet Amyloid. Diabetes, 2003, 52, 372-379.	0.3	105
82	Genetic Predictors of Weight Loss and Weight Regain After Intensive Lifestyle Modification, Metformin Treatment, or Standard Care in the Diabetes Prevention Program. Diabetes Care, 2012, 35, 363-366.	4.3	101
83	Quantifying Â-Cells in Health and Disease: The Past, the Present, and the Need. Diabetes Care, 2013, 36, 4-5.	4.3	101
84	Differential Effects of Abdominal Adipose Tissue Distribution on Insulin Sensitivity in Black and White South African Women. Obesity, 2009, 17, 1506-1512.	1.5	100
85	Treatment with a Somatostatin Analog Decreases Pancreatic B-Cell and Whole Body Sensitivity to Glucose*. Journal of Clinical Endocrinology and Metabolism, 1990, 71, 994-1002.	1.8	99
86	Impact of Intra-Abdominal Fat and Age on Insulin Sensitivity and Â-Cell Function. Diabetes, 2004, 53, 2867-2872.	0.3	98
87	Effects of Weight Loss, Weight Cycling, and Weight Loss Maintenance on Diabetes Incidence and Change in Cardiometabolic Traits in the Diabetes Prevention Program. Diabetes Care, 2014, 37, 2738-2745.	4.3	97
88	Cholesterol Feeding Increases C-Reactive Protein and Serum Amyloid A Levels in Lean Insulin-Sensitive Subjects. Circulation, 2005, 111, 3058-3062.	1.6	96
89	Comparison of a Clinical Model, the Oral Glucose Tolerance Test, and Fasting Glucose for Prediction of Type 2 Diabetes Risk in Japanese Americans. Diabetes Care, 2003, 26, 758-763.	4.3	95
90	Enhanced cortisol production rates, free cortisol, and 11β-HSD-1 expression correlate with visceral fat and insulin resistance in men: effect of weight loss. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E351-E357.	1.8	94

#	Article	IF	CITATIONS
91	Early beta cell dysfunction vs insulin hypersecretion as the primary event in the pathogenesis of dysglycaemia. Diabetologia, 2020, 63, 2007-2021.	2.9	94
92	Continuous Measurement of Oxygen Consumption by Pancreatic Islets. Diabetes Technology and Therapeutics, 2002, 4, 661-672.	2.4	92
93	Effects of Insulin Resistance and Obesity on Lipoproteins and Sensitivity to Egg Feeding. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1437-1443.	1.1	92
94	Insulin Response in Relation to Insulin Sensitivity. Diabetes Care, 2009, 32, 860-865.	4.3	92
95	Acute Effect of Roux-En-Y Gastric Bypass on Whole-Body Insulin Sensitivity: A Study with the Euglycemic-Hyperinsulinemic Clamp. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3871-3875.	1.8	90
96	The Visceral Adiposity Syndrome in Japaneseâ€American Men. Obesity, 1994, 2, 364-371.	4.0	89
97	Change in Visceral Adiposity Independently Predicts a Greater Risk of Developing Type 2 Diabetes Over 10 Years in Japanese Americans. Diabetes Care, 2013, 36, 289-293.	4.3	89
98	Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 5824-5829.	1.8	87
99	Long-Term Treatment With Rosiglitazone and Metformin Reduces the Extent of, but Does Not Prevent, Islet Amyloid Deposition in Mice Expressing the Gene for Human Islet Amyloid Polypeptide. Diabetes, 2005, 54, 2235-2244.	0.3	86
100	Direct Autocrine Action of Insulin on β-Cells: Does It Make Physiological Sense?. Diabetes, 2013, 62, 2157-2163.	0.3	85
101	Factors Associated With Diabetes Onset During Metformin Versus Placebo Therapy in the Diabetes Prevention Program. Diabetes, 2007, 56, 1153-1159.	0.3	84
102	Current Status of Islet Cell Replacement and Regeneration Therapy. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 1034-1043.	1.8	84
103	Patterns of Insulin Concentration During the OGTT Predict the Risk of Type 2 Diabetes in Japanese Americans. Diabetes Care, 2013, 36, 1229-1235.	4.3	84
104	Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD. Journal of the American Society of Nephrology: JASN, 2016, 27, 2861-2871.	3.0	83
105	Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study. Diabetes Care, 2019, 42, 601-608.	4.3	82
106	We Can Change the Natural History of Type 2 Diabetes. Diabetes Care, 2014, 37, 2668-2676.	4.3	75
107	Impact of Differences in Fasting Glucose and Glucose Tolerance on the Hyperbolic Relationship Between Insulin Sensitivity and Insulin Responses. Diabetes Care, 2006, 29, 356-362.	4.3	73
108	Low Clusterin Levels in High-Density Lipoprotein Associate With Insulin Resistance, Obesity, and Dyslipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 2528-2534.	1.1	72

#	Article	IF	CITATIONS
109	Genetic Predisposition to Weight Loss and Regain With Lifestyle Intervention: Analyses From the Diabetes Prevention Program and the Look AHEAD Randomized Controlled Trials. Diabetes, 2015, 64, 4312-4321.	0.3	72
110	Review of methods for measuring βâ€cell function: <scp>D</scp> esign considerations from the <scp>R</scp> estoring <scp>I</scp> nsulin <scp>S</scp> ecretion ( <scp>RISE</scp> ) <scp>C</scp> onsortium. Diabetes, Obesity and Metabolism, 2018, 20, 14-24.	2.2	71
111	COVID-19 in People With Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care, 2020, 43, 1378-1381.	4.3	71
112	Diet-Induced Weight Loss Is Associated with an Improvement in Î <sup>2</sup> -Cell Function in Older Men. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 2704-2710.	1.8	70
113	Improvement of BMI, Body Composition, and Body Fat Distribution With Lifestyle Modification in Japanese Americans With Impaired Glucose Tolerance. Diabetes Care, 2002, 25, 1504-1510.	4.3	69
114	Ethnic differences in serum lipoproteins and their determinants in South African women. Metabolism: Clinical and Experimental, 2010, 59, 1341-1350.	1.5	69
115	Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology, 2005, 128, 627-635.	0.6	68
116	Body Mass Index Is Associated with Increased Creatinine Clearance by a Mechanism Independent of Body Fat Distribution. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3781-3788.	1.8	68
117	Effect of 1 year of an intentional weight loss intervention on bone mineral density in type 2 diabetes: Results from the look AHEAD randomized trial. Journal of Bone and Mineral Research, 2012, 27, 619-627.	3.1	68
118	Islet amyloid formation is an important determinant for inducing islet inflammation in high-fat-fed human IAPP transgenic mice. Diabetologia, 2014, 57, 1884-1888.	2.9	68
119	Fibrinolytic response during exercise and epinephrine infusion in the same subjects. Journal of the American College of Cardiology, 1992, 19, 1412-1420.	1.2	66
120	Type 2 diabetes and the metabolic syndrome in Japanese Americans. Diabetes Research and Clinical Practice, 2000, 50, S73-S76.	1.1	66
121	Effects of Sex and Hormone Replacement Therapy Use on the Prevalence of Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance in Subjects With a Family History of Type 2 Diabetes. Diabetes, 2006, 55, 3529-3535.	0.3	65
122	Renal Function in Type 2 Diabetes with Rosiglitazone, Metformin, and Glyburide Monotherapy. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1032-1040.	2.2	64
123	Effect of Troglitazone on B Cell Function, Insulin Sensitivity, and Glycemic Control in Subjects with Type 2 Diabetes Mellitus <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 1998, 83, 819-823.	1.8	62
124	Preserved Cognition in Patients With Early Alzheimer Disease and Amnestic Mild Cognitive Impairment During Treatment With Rosiglitazone. American Journal of Geriatric Psychiatry, 2005, 13, 950-958.	0.6	62
125	A Reduced-Fat Diet and Aerobic Exercise in Japanese Americans With Impaired Glucose Tolerance Decreases Intra-Abdominal Fat and Improves Insulin Sensitivity but not A-Cell Function. Diabetes, 2005, 54, 340-347.	0.3	61
126	Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes Care, 2019, 42, 1809-1815.	4.3	61

#	Article	IF	CITATIONS
127	Relationship of Insulin Sensitivity and ApoB Levels to Intra-abdominal Fat in Subjects With Familial Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 567-572.	1.1	60
128	Visceral fat resection in humans: Effect on insulin sensitivity, betaâ€cell function, adipokines, and inflammatory markers. Obesity, 2013, 21, E182-9.	1.5	59
129	Effect of a long-term intensive lifestyle intervention on prevalence of cognitive impairment. Neurology, 2017, 88, 2026-2035.	1.5	59
130	Physical activity, sedentary behaviors, and estimated insulin sensitivity and secretion in pregnant and non-pregnant women. BMC Pregnancy and Childbirth, 2011, 11, 44.	0.9	58
131	Incretin Therapy and Islet Pathology: A Time for Caution. Diabetes, 2013, 62, 2178-2180.	0.3	57
132	The Effect of Intentional Weight Loss on Fracture Risk in Persons With Diabetes: Results From the Look AHEAD Randomized Clinical Trial. Journal of Bone and Mineral Research, 2017, 32, 2278-2287.	3.1	57
133	Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes. Diabetes Care, 2019, 42, 1742-1751.	4.3	56
134	Changes in body composition over 8 years in a randomized trial of a lifestyle intervention: The look AHEAD study. Obesity, 2015, 23, 565-572.	1.5	55
135	Increased Visceral Adipose Tissue Is an Independent Predictor for Future Development of Atherogenic Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 678-685.	1.8	54
136	Colesevelam Improves Oral but Not Intravenous Glucose Tolerance by a Mechanism Independent of Insulin Sensitivity and Î <sup>2</sup> -Cell Function. Diabetes Care, 2012, 35, 1119-1125.	4.3	51
137	Inhibition of glycosaminoglycan synthesis and protein glycosylation with WAS-406 and azaserine result in reduced islet amyloid formation in vitro. American Journal of Physiology - Cell Physiology, 2007, 293, C1586-C1593.	2.1	49
138	Modestly Elevated Glucose Levels During Pregnancy Are Associated With a Higher Risk of Future Diabetes Among Women Without Gestational Diabetes Mellitus. Diabetes Care, 2008, 31, 1037-1039.	4.3	49
139	The Association ofENPP1K121Q with Diabetes Incidence Is Abolished by Lifestyle Modification in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 449-455.	1.8	48
140	Does diabetes prevention translate into reduced long-term vascular complications of diabetes?. Diabetologia, 2019, 62, 1319-1328.	2.9	48
141	Relationship of Liver Enzymes to Insulin Sensitivity and Intra-Abdominal Fat. Diabetes Care, 2007, 30, 2673-2678.	4.3	47
142	Intensive Weight Loss Intervention and Cancer Risk in Adults with Type 2 Diabetes: Analysis of the Look AHEAD Randomized Clinical Trial. Obesity, 2020, 28, 1678-1686.	1.5	47
143	The relative associations of β-cell function and insulin sensitivity with glycemic status and incident glycemic progression in migrant Asian Indians in the United States: The MASALA study. Journal of Diabetes and Its Complications, 2014, 28, 45-50.	1.2	46
144	Hepatic Insulin Extraction in NAFLD Is Related to Insulin Resistance Rather Than Liver Fat Content. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1855-1865.	1.8	45

#	Article	lF	CITATIONS
145	Reduced Pancreatic B Cell Compensation to the Insulin Resistance of Aging: Impact on Proinsulin and Insulin Levels <sup>1</sup> . Journal of Clinical Endocrinology and Metabolism, 2000, 85, 2275-2280.	1.8	44
146	Paricalcitol does not improve glucose metabolism in patients with stage 3–4 chronic kidney disease. Kidney International, 2013, 83, 323-330.	2.6	44
147	Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. Diabetes Care, 2020, 43, 1803-1812.	4.3	44
148	Insulin, C-Peptide, and Leptin Concentrations Predict Increased Visceral Adiposity at 5- and 10-Year Follow-Ups in Nondiabetic Japanese Americans. Diabetes, 2005, 54, 985-990.	0.3	43
149	Factors Affecting the Decline in Incidence of Diabetes in the Diabetes Prevention Program Outcomes Study (DPPOS). Diabetes, 2015, 64, 989-998.	0.3	43
150	Effect of intensive endurance training on lipoprotein profiles in young and older men. Metabolism: Clinical and Experimental, 1992, 41, 649-654.	1.5	40
151	Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin Over 4 Years Despite Greater Weight Gain: Observations from A Diabetes Outcome Progression Trial (ADOPT). Diabetes Care, 2010, 33, 177-183.	4.3	40
152	Plasma sterol evidence for decreased absorption and increased synthesis of cholesterol in insulin resistance and obesity. American Journal of Clinical Nutrition, 2011, 94, 1182-1188.	2.2	40
153	Effect of heparin on insulin-glucose interactions measured by the minimal model technique: Implications for reproducibility using this method. Metabolism: Clinical and Experimental, 1993, 42, 353-357.	1.5	39
154	Gestational Diabetes or Lesser Degrees of Glucose Intolerance and Risk of Preeclampsia. Hypertension in Pregnancy, 2011, 30, 153-163.	0.5	39
155	Effects of Genetic Variants Previously Associated with Fasting Glucose and Insulin in the Diabetes Prevention Program. PLoS ONE, 2012, 7, e44424.	1.1	39
156	Ethnic differences in hepatic and systemic insulin sensitivity and their associated determinants in obese black and white South African women. Diabetologia, 2015, 58, 2647-2652.	2.9	39
157	Physical Function Following a Long-Term Lifestyle Intervention Among Middle Aged and Older Adults With Type 2 Diabetes: The Look AHEAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2018, 73, 1552-1559.	1.7	39
158	Insulin resistance and obesity. Nature, 1999, 402, 860-861.	13.7	38
159	Proteoglycans synthesized and secreted by pancreatic islet β-cells bind amylin. Archives of Biochemistry and Biophysics, 2003, 413, 182-190.	1.4	38
160	Importance of Early Phase Insulin Secretion to Intravenous Glucose Tolerance in Subjects with Type 2 Diabetes Mellitus. , 0, .		38
161	Insulin and Amylin Release Are Both Diminished in First-Degree Relatives of Subjects With Type 2 Diabetes. Diabetes Care, 2002, 25, 292-297.	4.3	37
162	Insulin Resistance is the Best Predictor of the Metabolic Syndrome in Subjects With a Firstâ€Degree Relative With Type 2 Diabetes. Obesity, 2010, 18, 1781-1787.	1.5	37

#	Article	IF	CITATIONS
163	Triglyceride Response to an Intensive Lifestyle Intervention Is Enhanced in Carriers of the <i>GCKR</i> Pro446Leu Polymorphism. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1142-E1147.	1.8	37
164	Risk factors for type 2 diabetes: Lessons learned from Japanese Americans in Seattle. Journal of Diabetes Investigation, 2012, 3, 212-224.	1.1	37
165	The S20G substitution in hIAPP is more amyloidogenic and cytotoxic than wild-type hIAPP in mouse islets. Diabetologia, 2016, 59, 2166-2171.	2.9	37
166	Reduced Gluteal Expression of Adipogenic and Lipogenic Genes in Black South African Women Is Associated with Obesity-Related Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E2029-E2033.	1.8	36
167	Variation at the melanocortin 4 receptor gene and response to weight″oss interventions in the diabetes prevention program. Obesity, 2013, 21, E520-6.	1.5	36
168	Change in Intra-Abdominal Fat Predicts the Risk of Hypertension in Japanese Americans. Hypertension, 2015, 66, 134-140.	1.3	36
169	Low Plasma Adiponectin Concentrations Predict Increases in Visceral Adiposity and Insulin Resistance. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4626-4633.	1.8	36
170	Glucose- and time-dependence of islet amyloid formation in vitro. Biochemical and Biophysical Research Communications, 2007, 354, 234-239.	1.0	35
171	Neprilysin Impedes Islet Amyloid Formation by Inhibition of Fibril Formation Rather Than Peptide Degradation. Journal of Biological Chemistry, 2010, 285, 18177-18183.	1.6	35
172	Association of Thigh Muscle Mass with Insulin Resistance and Incident Type 2 Diabetes Mellitus in Japanese Americans. Diabetes and Metabolism Journal, 2018, 42, 488.	1.8	35
173	Novel approaches to restore beta cell function in prediabetes and type 2 diabetes. Diabetologia, 2018, 61, 1895-1901.	2.9	35
174	Reduced β-cell function contributes to impaired glucose tolerance in dogs made obese by high-fat feeding. American Journal of Physiology - Endocrinology and Metabolism, 1999, 277, E659-E667.	1.8	34
175	PLTP activity decreases with weight loss. Journal of Lipid Research, 2003, 44, 1705-1712.	2.0	34
176	Midcourse correction to a clinical trial when the event rate is underestimated: the Look AHEAD (Action for Health in Diabetes) Study. Clinical Trials, 2012, 9, 113-124.	0.7	34
177	Lifestyle and Metformin Ameliorate Insulin Sensitivity Independently of the Genetic Burden of Established Insulin Resistance Variants in Diabetes Prevention Program Participants. Diabetes, 2016, 65, 520-526.	0.3	34
178	Evidence That the Sympathetic Nervous System Elicits Rapid, Coordinated, and Reciprocal Adjustments of Insulin Secretion and Insulin Sensitivity During Cold Exposure. Diabetes, 2017, 66, 823-834.	0.3	34
179	Identification of the Amyloid-Degrading Enzyme Neprilysin in Mouse Islets and Potential Role in Islet Amyloidogenesis. Diabetes, 2007, 56, 304-310.	0.3	33
180	The Look AHEAD Trial: Bone Loss at 4-Year Follow-up in Type 2 Diabetes. Diabetes Care, 2014, 37, 2822-2829.	4.3	33

#	Article	IF	CITATIONS
181	Matrix Metalloproteinase-9 Reduces Islet Amyloid Formation by Degrading Islet Amyloid Polypeptide. Journal of Biological Chemistry, 2013, 288, 3553-3559.	1.6	32
182	Changes in insulin sensitivity, glucose effectiveness, and B-cell function in regularly exercising subjects. Metabolism: Clinical and Experimental, 1995, 44, 1259-1263.	1.5	30
183	Human aging is associated with parallel reductions in insulin and amylin release. American Journal of Physiology - Endocrinology and Metabolism, 1998, 275, E785-E791.	1.8	30
184	Islet dysfunction in non-insulin-dependent diabetes mellitus. American Journal of Medicine, 1988, 85, 4-8.	0.6	27
185	Impact of Gastric Banding Versus Metformin on β-Cell Function in Adults With Impaired Glucose Tolerance or Mild Type 2 Diabetes. Diabetes Care, 2018, 41, 2544-2551.	4.3	27
186	Serum ferritin is associated with non-alcoholic fatty liver disease and decreased Î'-cell function in non-diabetic men and women. Journal of Diabetes and Its Complications, 2014, 28, 177-184.	1.2	26
187	Hepatic Insulin Resistance Following Chronic Activation of the CREB Coactivator CRTC2. Journal of Biological Chemistry, 2015, 290, 25997-26006.	1.6	26
188	Mechanisms for hyperglycemia in type II diabetes mellitus: Therapeutic implications for sulfonylurea treatment—an update. American Journal of Medicine, 1991, 90, S8-S14.	0.6	25
189	Des-(27-31)C-Peptide. Journal of Biological Chemistry, 1996, 271, 27475-27481.	1.6	25
190	Effects of Short-Term Experimental Insulin Resistance and Family History of Diabetes on Pancreatic β-Cell Function in Nondiabetic Individuals. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5825-5833.	1.8	25
191	Weight Change 2 Years After Termination of the Intensive Lifestyle Intervention in the Look AHEAD Study. Obesity, 2020, 28, 893-901.	1.5	24
192	Latent class analysis of the metabolic syndrome. Diabetes Research and Clinical Practice, 2010, 89, 88-93.	1.1	23
193	Intra-abdominal fat accumulation is greatest at younger ages in Japanese-American adults. Diabetes Research and Clinical Practice, 2010, 89, 58-64.	1.1	23
194	Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care, 2022, 45, 1252-1259.	4.3	23
195	Human Cardiovascular Disease IBC Chip-Wide Association with Weight Loss and Weight Regain in the Look AHEAD Trial. Human Heredity, 2013, 75, 160-174.	0.4	22
196	Type 2 Diabetes Subgroups, Risk for Complications, and Differential Effects Due to an Intensive Lifestyle Intervention. Diabetes Care, 2021, 44, 1203-1210.	4.3	22
197	Differential Association Between HDL Subclasses and the Development of Type 2 Diabetes in a Prospective Study of Japanese Americans. Diabetes Care, 2015, 38, 2100-2105.	4.3	21
198	A Call for Improved Reporting of Human Islet Characteristics in Research Articles. Diabetes, 2019, 68, 239-240.	0.3	21

#	Article	IF	CITATIONS
199	The β Cell in Diabetes: Integrating Biomarkers With Functional Measures. Endocrine Reviews, 2021, 42, 528-583.	8.9	21
200	The Influence of Rare Genetic Variation in <i>SLC30A8</i> on Diabetes Incidence and β-Cell Function. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E926-E930.	1.8	20
201	Physical activity and metabolic health in chronic kidney disease: a cross-sectional study. BMC Nephrology, 2016, 17, 187.	0.8	20
202	OGTT Glucose Response Curves, Insulin Sensitivity, and β-Cell Function in RISE: Comparison Between Youth and Adults at Randomization and in Response to Interventions to Preserve β-Cell Function. Diabetes Care, 2021, 44, 817-825.	4.3	20
203	Superior vena caval obstruction secondary to acute dissecting aneurysm of the aorta. American Heart Journal, 1986, 111, 606-608.	1.2	19
204	Neprilysin Deficiency Protects Against Fat-Induced Insulin Secretory Dysfunction by Maintaining Calcium Influx. Diabetes, 2013, 62, 1593-1601.	0.3	19
205	SGLT2 Inhibitors—Sweet Success for Diabetic Kidney Disease?. Journal of the American Society of Nephrology: JASN, 2017, 28, 7-10.	3.0	19
206	Metabolic Clusters and Outcomes in Older Adults: The Cardiovascular Health Study. Journal of the American Geriatrics Society, 2018, 66, 289-296.	1.3	19
207	A call for improved reporting of human islet characteristics in research articles. Diabetologia, 2019, 62, 209-211.	2.9	19
208	An Exercise Intervention to Unravel the Mechanisms Underlying Insulin Resistance in a Cohort of Black South African Women: Protocol for a Randomized Controlled Trial and Baseline Characteristics of Participants. JMIR Research Protocols, 2018, 7, e75.	0.5	19
209	Determination of Optimal Sample Size for Quantification of β-Cell Area, Amyloid Area and β-Cell Apoptosis in Isolated Islets. Journal of Histochemistry and Cytochemistry, 2015, 63, 663-673.	1.3	18
210	Population approaches to estimate minimal model indexes of insulin sensitivity and glucose effectiveness using full and reduced sampling schedules. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E716-E723.	1.8	17
211	Reduced Adipogenic Gene Expression in Thigh Adipose Tissue Precedes Human Immunodeficiency Virus-Associated Lipoatrophy. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 959-966.	1.8	17
212	Apoptosis Repressor With Caspase Recruitment Domain Ameliorates Amyloid-Induced β-Cell Apoptosis and JNK Pathway Activation. Diabetes, 2017, 66, 2636-2645.	0.3	17
213	Adipocytokines as features of the metabolic syndrome determined using confirmatory factor analysis. Annals of Epidemiology, 2013, 23, 415-421.	0.9	16
214	Impact of differences in glucose tolerance on the prevalence of a negative insulinogenic index. Journal of Diabetes and Its Complications, 2013, 27, 158-161.	1.2	16
215	Maternal Physical Activity and Insulin Action in Pregnancy and Their Relationships With Infant Body Composition. Diabetes Care, 2013, 36, 267-269.	4.3	16
216	Variation in Maturity-Onset Diabetes of the Young Genes Influence Response to Interventions for Diabetes Prevention. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2678-2689.	1.8	16

#	Article	IF	CITATIONS
217	Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. Diabetes Care, 2021, 44, 340-349.	4.3	16
218	Obstructive Sleep Apnea, Glucose Tolerance, and β-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 993-1001.	4.3	16
219	Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2021, 44, 1938-1947.	4.3	16
220	Glucose Control in Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2009, 301, 1590.	3.8	14
221	Effect of exercise training on insulin sensitivity, hyperinsulinemia and ectopic fat in black South African women: a randomized controlled trial. European Journal of Endocrinology, 2020, 183, 51-61.	1.9	14
222	A Polygenic Lipodystrophy Genetic Risk Score Characterizes Risk Independent of BMI in the Diabetes Prevention Program. Journal of the Endocrine Society, 2019, 3, 1663-1677.	0.1	13
223	Interaction Between Type 2 Diabetes Prevention Strategies and Genetic Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors. Diabetes, 2020, 69, 112-120.	0.3	13
224	Impaired counterregulatory responses to hypoglycaemia following oral glucose in adults with cystic fibrosis. Diabetologia, 2020, 63, 1055-1065.	2.9	13
225	Matrix Metalloproteinase-9 Protects Islets from Amyloid-induced Toxicity. Journal of Biological Chemistry, 2015, 290, 30475-30485.	1.6	12
226	Medications for type 2 diabetes: how will we be treating patients in 50Âyears?. Diabetologia, 2015, 58, 1735-1739.	2.9	12
227	Genetic ancestry markers and difference in A1c between African-American and White in the Diabetes Prevention Program. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 328-336.	1.8	12
228	Short Report: Circulating microRNAs are associated with incident diabetes over 10 years in Japanese Americans. Scientific Reports, 2020, 10, 6509.	1.6	12
229	Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin. BMJ Open Diabetes Research and Care, 2021, 9, e002264.	1.2	12
230	Prospective evaluation of β-cell function in insulin antoantibody-positive relatives of insulin-dependent diabetic patients. Metabolism: Clinical and Experimental, 1993, 42, 482-486.	1.5	11
231	Effect of Human Growth Hormone and Insulin-Like Growth Factor I on Whole-Body Leucine and Estimates of Protein Metabolism. Hormone Research, 1993, 40, 92-94.	1.8	11
232	Superiority of the Modification of Diet in Renal Disease equation over the Cockcroft–Gault equation in screening for impaired kidney function in Japanese Americans. Diabetes Research and Clinical Practice, 2007, 77, 320-326.	1.1	11
233	Effects of combination of change in visceral fat and thigh muscle mass on the development of type 2 diabetes. Diabetes Research and Clinical Practice, 2017, 134, 131-138.	1.1	11
234	Relationships of the early insulin secretory response and oral disposition index with gastric emptying in subjects with normal glucose tolerance. Physiological Reports, 2017, 5, e13122.	0.7	11

#	Article	IF	CITATIONS
235	Islet Autoimmunity Is Highly Prevalent and Associated With Diminished Î <sup>2</sup> -Cell Function in Patients With Type 2 Diabetes in the GRADE Study. Diabetes, 2022, 71, 1261-1271.	0.3	11
236	Management of patients with diabetic hyperlipidemia. American Journal of Cardiology, 2003, 91, 24-28.	0.7	10
237	Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E703-E709.	1.8	10
238	Greater visceral abdominal fat is associated with a lower probability of conversion of prehypertension to normotension. Journal of Hypertension, 2017, 35, 1213-1218.	0.3	10
239	Low concentration IL-1Î <sup>2</sup> promotes islet amyloid formation by increasing hIAPP release from humanised mouse islets in vitro. Diabetologia, 2020, 63, 2385-2395.	2.9	10
240	Within-Trial Cost-Effectiveness of a Structured Lifestyle Intervention in Adults With Overweight/Obesity and Type 2 Diabetes: Results From the Action for Health in Diabetes (Look AHEAD) Study. Diabetes Care, 2021, 44, 67-74.	4.3	10
241	Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial. Diabetes Care, 2022, 45, 742-749.	4.3	10
242	Engineering a new β-cell: a critical venture requiring special attention to constantly changing physiological needs. Seminars in Cell and Developmental Biology, 2004, 15, 359-370.	2.3	9
243	Association of Habitual Daily Physical Activity With Glucose Tolerance and β-Cell Function in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes From the Restoring Insulin Secretion (RISE) Study. Diabetes Care, 2019, 42, 1521-1529.	4.3	9
244	Higher High Density Lipoprotein 2 (HDL2) to Total HDL Cholesterol Ratio Is Associated with a Lower Risk for Incident Hypertension. Diabetes and Metabolism Journal, 2019, 43, 114.	1.8	9
245	Hyperglucagonemia Does Not Explain the β-Cell Hyperresponsiveness and Insulin Resistance in Dysglycemic Youth Compared With Adults: Lessons From the RISE Study. Diabetes Care, 2021, 44, 1961-1969.	4.3	9
246	Low-dose streptokinase therapy for Swan-Ganz catheter-induced thrombosis. American Heart Journal, 1985, 110, 891-893.	1.2	8
247	Change in visceral adiposity is an independent predictor of future arterial pulse pressure. Journal of Hypertension, 2018, 36, 299-305.	0.3	8
248	Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice. Diabetologia, 2018, 61, 2215-2224.	2.9	8
249	Loss of perlecan heparan sulfate glycosaminoglycans lowers body weight and decreases islet amyloid deposition in human islet amyloid polypeptide transgenic mice. Protein Engineering, Design and Selection, 2019, 32, 95-102.	1.0	8
250	History of Cardiovascular Disease, Intensive Lifestyle Intervention, and Cardiovascular Outcomes in the Look AHEAD Trial. Obesity, 2020, 28, 247-258.	1.5	8
251	A Lesson From 2020: Public Health Matters for Both COVID-19 and Diabetes. Diabetes Care, 2021, 44, 8-10.	4.3	8
252	Apolipoprotein B Levels Predict Future Development of Hypertension Independent of Visceral Adiposity and Insulin Sensitivity. Endocrinology and Metabolism, 2020, 35, 351-358.	1.3	8

#	Article	IF	CITATIONS
253	Suppression of Beta-Cell Secretion by Somatostatin Does Not Fully Reverse the Disproportionate Proinsulinemia of Type 2 Diabetes. Diabetes, 2004, 53, S22-S25.	0.3	7
254	<i>Diabetes Care</i> : "Taking It to the Limit One More Time― Diabetes Care, 2017, 40, 3-6.	4.3	7
255	Design and validation of a novel estimator of visceral adipose tissue area and comparison to existing adiposity surrogates. Journal of Diabetes and Its Complications, 2018, 32, 1062-1067.	1.2	7
256	Withdrawal of medications leads to worsening of <scp>OGTT</scp> parameters in youth with impaired glucose tolerance or <scp>recentlyâ€diagnosed</scp> type 2 diabetes. Pediatric Diabetes, 2020, 21, 1437-1446.	1.2	7
257	Sexâ€related differences in cognitive trajectories in older individuals with type 2 diabetes and overweight or obesity. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2021, 7, e12160.	1.8	7
258	Lifestyle Intervention for Weight Loss and Cardiometabolic Changes in the Setting of Glucokinase Regulatory Protein Inhibition. Circulation: Cardiovascular Genetics, 2016, 9, 71-78.	5.1	6
259	Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial. CKJ: Clinical Kidney Journal, 2021, 14, 226-236.	1.4	6
260	On the causal relationships between hyperinsulinaemia, insulin resistance, obesity and dysglycaemia in type 2 diabetes: Reply to Johnson JD [letter]. Diabetologia, 2021, 64, 2345-2347.	2.9	6
261	Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Na¬ve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Frontiers in Immunology, 2021, 12, 640251.	2.2	6
262	Transfemoral embolectomy for massive pulmonary embolus and associated myocardial infarction. American Heart Journal, 1987, 113, 819-822.	1.2	5
263	Point: Recent Long-Term Clinical Studies Support an Enhanced Role for Thiazolidinediones in the Management of Type 2 Diabetes. Diabetes Care, 2007, 30, 1672-1676.	4.3	5
264	A Novel Risk Classification Paradigm for Patients With Impaired Glucose Tolerance and High Cardiovascular Risk. American Journal of Cardiology, 2013, 112, 231-237.	0.7	5
265	Inhibition of Insulin-Degrading Enzyme Does Not Increase Islet Amyloid Deposition in Vitro. Endocrinology, 2016, 157, 3462-3468.	1.4	5
266	Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp. American Journal of Physiology - Endocrinology and Metabolism, 2017, 312, E175-E182.	1.8	5
267	RNA-seq-based identification of Star upregulation by islet amyloid formation. Protein Engineering, Design and Selection, 2019, 32, 67-76.	1.0	5
268	Probing the Meaning of Persistent Propeptide Release in Type 1 Diabetes. Diabetes Care, 2019, 42, 183-185.	4.3	5
269	Change in CT-measured abdominal subcutaneous and visceral but not thigh fat areas predict future insulin sensitivity. Diabetes Research and Clinical Practice, 2019, 154, 17-26.	1.1	5
270	Comparison of twenty indices of insulin sensitivity in predicting type 2 diabetes in Japanese Americans: The Japanese American Community Diabetes Study. Journal of Diabetes and Its Complications, 2020, 34, 107731.	1.2	5

#	Article	IF	CITATIONS
271	Association of glycemia with insulin sensitivity and β-cell function in adults with early type 2 diabetes on metformin alone. Journal of Diabetes and Its Complications, 2021, 35, 107912.	1.2	5
272	Changes in mood and healthâ€related quality of life in Look AHEAD 6 years after termination of the lifestyle intervention. Obesity, 2021, 29, 1294-1308.	1.5	5
273	Legacy of a 10-Year Multidomain Lifestyle Intervention on the Cognitive Trajectories of Individuals with Overweight/Obesity and Type 2 Diabetes Mellitus. Dementia and Geriatric Cognitive Disorders, 2021, 50, 237-249.	0.7	5
274	Regulation of Insulin Secretion in Vivo. Growth Hormone, 2001, , 109-131.	0.2	5
275	Response to Comments on Nolan et al. Insulin Resistance as a Physiological Defense Against Metabolic Stress: Implications for the Management of Subsets of Type 2 Diabetes. Diabetes 2015;64:673–686. Diabetes, 2015, 64, e38-e39.	0.3	4
276	Leptin and Adiponectin Concentrations Independently Predict Future Accumulation of Visceral Fat in Nondiabetic Japanese Americans. Obesity, 2021, 29, 233-239.	1.5	4
277	Precision and accuracy of hyperglycemic clamps in a multicenter study. American Journal of Physiology - Endocrinology and Metabolism, 2021, 320, E797-E807.	1.8	4
278	Intra-Abdominal Fat and High Density Lipoprotein Cholesterol Are Associated in a Non-Linear Pattern in Japanese-Americans. Diabetes and Metabolism Journal, 2020, 44, 277.	1.8	4
279	Association Between the 4 bp Proinsulin Gene Insertion Polymorphism (IVSâ€69) and Body Composition in Black South African Women. Obesity, 2009, 17, 1298-1300.	1.5	3
280	Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level. Diabetes and Metabolism Journal, 2018, 42, 198.	1.8	3
281	Tubular Secretory Clearance Is Associated With Whole-Body Insulin Clearance. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3882-e3891.	1.8	3
282	Daniel Porte Jr.: A Leader in Our Understanding of the Role of Defective Insulin Secretion and Action in Obesity and Type 2 Diabetes. Diabetes Care, 2020, 43, 704-709.	4.3	3
283	β-cell function in black South African women: exploratory associations with insulin clearance, visceral and ectopic fat. Endocrine Connections, 2021, 10, 550-560.	0.8	3
284	Glucose Control, Macro- and Microvascular Disease, and the Food and Drug Administration: Let's Keep Our Eye on the Ball. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 3727-3729.	1.8	2
285	What's Next for Diabetes Prevention?. Diabetes Care, 2011, 34, 1678-1680.	4.3	2
286	Effect of Medical and Surgical Interventions on α-Cell Function in Dysglycemic Youth and Adults in the RISE Study. Diabetes Care, 2021, 44, 1948-1960.	4.3	2
287	Lower High-Density Lipoprotein Cholesterol Concentration Is Independently Associated with Greater Future Accumulation of Intra-Abdominal Fat. Endocrinology and Metabolism, 2021, 36, 835-844.	1.3	2
288	Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naìve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study. Frontiers in Immunology, 2021, 12, 640251.	2.2	2

#	ARTICLE	IF	CITATIONS
289	Adiposity, related biomarkers, and type 2 diabetes after gestational diabetes: The Diabetes Prevention Program. Obesity, 2021, , .	1.5	2
290	Plasma amino acid profile, a biomarker for visceral adipose tissue that can substitute for waist circumference in Japanese Americans. Obesity Research and Clinical Practice, 2021, 15, 557-563.	0.8	2
291	Of Hopes and DREAMS: The Quest to Prevent Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 4762-4763.	1.8	1
292	Michaela Diamant, 11 April 1962–9 April 2014. Diabetologia, 2014, 57, 1271-1272.	2.9	1
293	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a <i>Diabetes Care</i> Editors' Expert Forum. Diabetes Care 2016;39:1186–1201. Diabetes Care, 2017, 40, e23-e24.	4.3	1
294	Natural history of impaired glucose tolerance in Japanese Americans: Change in visceral adiposity is associated with remission from impaired glucose tolerance to normal glucose tolerance. Diabetes Research and Clinical Practice, 2018, 142, 303-311.	1.1	1
295	Treatment with Thiazolidinediones. , 2013, , 117-146.		0
296	Loss of apoptosis repressor with caspase recruitment domain (ARC) worsens high fat diet-induced hyperglycemia in mice. Journal of Endocrinology, 2021, 251, 125-135.	1.2	0
297	Predictors of Incident Type 2 Diabetes Mellitus in Japanese Americans with Normal Fasting Glucose Level. Diabetes and Metabolism Journal, 2018, , .	1.8	0
298	Editorial Cycles and Continuity of <i>Diabetes Care</i> . Diabetes Care, 2022, 45, 1493-1494.	4.3	0